Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

202.28B

Market cap202.28B

Price-Earnings ratio

26.02

Price-Earnings ratio26.02

Dividend yield

2.62%

Dividend yield2.62%

Average volume

3.08M

Average volume3.08M

High today

$375.15

High today$375.15

Low today

$362.88

Low today$362.88

Open price

$365.22

Open price$365.22

Volume

2.49M

Volume2.49M

52 Week high

$391.29

52 Week high$391.29

52 Week low

$269.77

52 Week low$269.77

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $372.67. The company's market cap stands at 202.28B, with a P/E ratio of 26.02 and a dividend yield of 2.62%.

During the trading session on 2026-07-03, Amgen(AMGN) shares reached a daily high of $375.15 and a low of $362.88. At a current price of $372.67, the stock is +2.7% higher than the low and still -0.7% under the high.

Trading activity shows a volume of 2.49M, compared to an average daily volume of 3.08M.

The stock's 52-week range extends from a low of $269.77 to a high of $391.29.

AMGN News

TipRanks 22h

Amgen’s Rocatinlimab Asthma Trial Reaches Phase 2 Finish Line

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...

Simply Wall St 1d

Does Tavneos Retraction And Possible Withdrawal Reshape The Bull Case For Amgen?

The New England Journal of Medicine has retracted the pivotal Tavneos study and, following regulatory concerns over severe liver injuries, both the FDA and Euro...

Benzinga 2d

Micron, Palo Alto, Apple And A Health Care Stock On CNBC’s ‘Final Trades’

Supporting his view, Cantor Fitzgerald analyst C.J. Muse maintained Micron with an Overweight rating on June 29 and raised the price target from $1,500 to $2,00...

Analyst ratings

50%

of 34 ratings

Buy

38.2%

Hold

50%

Sell

11.8%

More AMGN News

Nasdaq 3d

Alphabet Just Joined the Dow Jones Industrial Average. 3 Dow Dividend Stocks to Buy Now.

Key Points Cisco Systems is on a roll with its AI-powered platform. Coca-Cola saw volume growth in each of its marketing segments in the first quarter. Amgen...

TipRanks 4d

Trial used to approve Amgen’s Tavneos retracted from NEJM

A clinical trial, originally published in 2021, which was used to approve Amgen’s (AMGN) Tavneos was retracted Monday from the New England Journal of Medicine a...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.